1034 related articles for article (PubMed ID: 11316005)
1. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
[TBL] [Abstract][Full Text] [Related]
2. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
[TBL] [Abstract][Full Text] [Related]
3. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
Ke HZ; Foley GL; Simmons HA; Shen V; Thompson DD
Endocrinology; 2004 Apr; 145(4):1996-2005. PubMed ID: 14726439
[TBL] [Abstract][Full Text] [Related]
5. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
[TBL] [Abstract][Full Text] [Related]
6. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
7. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
9. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
10. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats.
Cui L; Wu T; Liu YY; Deng YF; Ai CM; Chen HQ
Acta Pharmacol Sin; 2004 May; 25(5):678-84. PubMed ID: 15132837
[TBL] [Abstract][Full Text] [Related]
12. Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats.
Li M; Healy DR; Li Y; Simmons HA; Su M; Jee WS; Shen VW; Thompson DD
J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):22-32. PubMed ID: 15615075
[TBL] [Abstract][Full Text] [Related]
13. Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats.
Xu D; Yang W; Zhou C; Liu Y; Xu B
Planta Med; 2010 Nov; 76(16):1809-13. PubMed ID: 20577944
[TBL] [Abstract][Full Text] [Related]
14. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
15. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
16. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.
Bourrin S; Ammann P; Bonjour JP; Rizzoli R
Bone; 2002 Jan; 30(1):195-200. PubMed ID: 11792585
[TBL] [Abstract][Full Text] [Related]
17. Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model.
Ardawi MM; Badawoud MH; Hassan SM; Rouzi AA; Ardawi JMS; AlNosani NM; Qari MH; Mousa SA
Bone; 2016 Feb; 83():127-140. PubMed ID: 26549245
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats.
Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
Exp Anim; 2006 Jul; 55(4):357-67. PubMed ID: 16880683
[TBL] [Abstract][Full Text] [Related]
19. Energy-restricted diet benefits body composition but degrades bone integrity in middle-aged obese female rats.
Shen CL; Zhu W; Gao W; Wang S; Chen L; Chyu MC
Nutr Res; 2013 Aug; 33(8):668-76. PubMed ID: 23890357
[TBL] [Abstract][Full Text] [Related]
20. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction.
Yoshida Y; Moriya A; Kitamura K; Inazu M; Okimoto N; Okazaki Y; Nakamura T
J Bone Miner Res; 1998 Jun; 13(6):1011-22. PubMed ID: 9626633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
